Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Novartis Primed To Re-Energize Respiratory Business, Rivals Close In

Wed, 10/02/2019 - 8:58am

Novartis’s once-daily triple combination inhaler, QVM149, and dual inhaler, QMF149, could be the first to gain approval for the treatment...

      Related Stories 

Novartis Eyes Fourth Approval For Cosentyx

Wed, 10/02/2019 - 7:19am

As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's...

      Related Stories 

Facing Regulatory Heat, Indian Pharma Turns To Quality Solutions

Tue, 10/01/2019 - 5:20pm

Against a backdrop of US FDA warnings and global regulatory convergence, the Indian pharma industry is looking to build in...

      Related Stories 

R&D Head Ehlers Bows Out As Confidence In Biogen's Pipeline Suffers From Setbacks

Tue, 10/01/2019 - 3:08pm

EVP Michael Ehlers swaps public company scrutiny for early-stage, venture-funded opportunities at Apple Tree Partners and Limelight Bio, while CMO...

      Related Stories 

Novartis Ramps Up Digital Transformation With Microsoft AI Deal

Tue, 10/01/2019 - 12:54pm

New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding...

      Related Stories 

Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

Tue, 10/01/2019 - 11:01am

Overall survival for patients with gastrointestinal stromal tumors (GIST) in the fourth-line setting was 15.1 months versus 6.6 months for...

      Related Stories 

BMS’s Opdivo On Track For Esophageal Cancer Indication

Tue, 10/01/2019 - 10:51am

Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy...

      Related Stories 

'Intriguing' data on GSK's ICOS Agonist For Head and Neck Cancer

Tue, 10/01/2019 - 6:05am

As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with...

      Related Stories 

Keytruda Poised To Add Early TNBC To Its Resumé As KEYNOTE-522 Hits First Endpoint

Mon, 09/30/2019 - 1:38pm

A first look at data from Merck & Co’s KEYNOTE-522 trial of Keytruda in early triple-negative breast cancer showed significant...

      Related Stories 

Lynparza Poised To Bring Targeted Therapy To Prostate Cancer

Mon, 09/30/2019 - 12:41pm

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous...

      Related Stories 

Pages